 |
| ▲ Yoo Gee-seung, CEO of Seqirus Korea Ltd., speaks during an online press conference on Feb. 16, 2022, in this photo provided by the vaccine maker. (PHOTO NOT FOR SALE) (Yonhap) |
Seqirus-S Korea
Seqirus eyes swift introduction of influenza vaccines into S. Korea
By Kim Han-joo
SEOUL, Feb. 16 (Yonhap) -- Global leading influenza vaccine maker Seqirus Ltd. said it will swiftly bring its various products into South Korea amid the yearslong pandemic.
Seqirus, part of Australia-based biotech firm CSL Ltd., is one of the largest influenza vaccine companies in the world with pipelines in the U.S., Britain and Australia. The company provides influenza vaccines to over 20 countries.
Seqirus set up its local corporate body, Seqirus Korea Ltd., in 2017.
"We will try our best to bring various Seqirus vaccines into the country as quickly as possible," Seqirus Korea CEO Yoo Gee-seung said during an online press conference.
Yoo also highlighted the importance of administering an influenza vaccine at the right time to boost its effectiveness after mid-October, especially as the COVID-19 pandemic continues.
Seqirus currently provides its influenza virus vaccine, Afluria Quadrivalent, in South Korea. The product can be used on adults, as well as children aged five or older.
The company said it plans to bring in two other influenza vaccines -- Fluad Quadrivalent and Flucelvax Quadrivalent -- sometime soon.
(END)
(C) Yonhap News Agency. All Rights Reserved
